Welcome to the Virtual 2021 Advanced Heart Failure Symposium
This virtual two-day symposium will provide an in-depth perspective on the treatment of the patient with advanced heart failure. Experts in the field will provide attendees with information on the most recent treatment recommendations including current medical, surgical, and investigational therapies for patients with advanced heart failure. This symposium was designed to meet the educational needs of RNs and NPs involved in the diagnosis and care of patients with Advanced Heart Failure across practice settings.
Each session opens 15 minutes prior to the start time. To access live sessions, click the "Sessions" tab and select the desired session.
Friday, October 8: 7:35 am - 5:00 pm EST
Saturday, October 9: 8:00 am - 4:45 pm EST
Exhibit Hall Schedule
Interact with Exhibitors, view their products and promotions by selecting the “Virtual Exhibit Hall" tab.
Friday, October 8: 7:00 am - 7:35 am/9:45 am - 10:00 am/11:45 am - 12:15 pm/2:15 pm - 2:30 pm EST
Saturday, October 9: 7:00 am - 8:00 am/10:00 am - 10:15 am/12:00 pm - 12:30 pm/3:15 pm - 3:30 pm EST
Accreditation Statement
This activity is provided by the American Association of Heart Failure Nurses (AAHFN). The American Association of Heart Failure Nurses (AAHFN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.
Learning Outcome/ Purpose
The Advanced Heart Failure Symposium seeks to improve the understanding and practice of nurses and nurse practitioners by providing lectures, discussion, case studies incorporating the most recent innovations and management strategies in the care of advanced heart failure (HF) patients. The learner will develop an understanding of when to refer this patient population for advanced heart failure therapies as well as other considerations such as the utilization of biomarkers, hemodynamic monitoring, right heart failure, treatment of cardiogenic shock, long-term device options, and HF management without advanced HF therapies. They will also look for and diagnose cardiac amyloidosis earlier and refer for therapy.
Contact Hours
Attendees may earn (up to) 13.75 contact hours by attending this activity and completing the evaluation.
Claiming Contact Hours
Attendees can earn one nursing contact hour for every hour of educational time. Learners must complete an evaluation to receive contact hours. The evaluation is available after the activity.
Disclosure/Conflicts of Interest
The planners and faculty for this activity do not have any relevant relationships to disclose unless listed below. Any resulting conflicts of interest have been resolved according to ANCC guidance.
Marie Galvao, MSN, ANP-BC, CHFN
Consultant to Boston Scientific
Steering Committee member for MANAGE-HF
Lee Goldberg, MD, MPH
Respircardia - Consultant
Abbott - Consultant
Aroti Hegde, MD
Nuwellis Inc.: Member of Medical Advisory BoardDaniel Judge, MD, FACC, FHFSA
Consultant for ADRx Biopharma, 4D Molecular Therapeutics, Cytokinetics, Pfizer, and Tenaya Therapeutics
Daniel Judge, MD, FACC, FHFSA
Consultant for ADRx Biopharma, 4D Molecular Therapeutics, Cytokinetics, Pfizer, and Tenaya Therapeutics
Susheel Koldali, MD
Consultant (Honoraria) - Admedus, Dura Biotech, TriCares
SAB (Equity) - Dura Biotech, MicroInterventional Devices, Thubrikar Aortic Valve Inc, Supira, Admedus, TriFlo, Adona
Institutional Funding - Edwards Lifesciences, Medtronic, Abbott Vascular, Boston Scientific, JenaValve
Samer Najjar, MD
Abbott: Institutional research support and consultant
Medtronic: Institutional research support
George Ruiz, MD, MBA
United Therapeutics, Consultant
Joyce Wald, DO
Participate in Abbott supported research
Disclosure of Commercial Support
AAHFN did not receive commercial support for this activity.
This live activity is valid from October 8 – 15, 2021.
This on-demand activity is valid from October 15, 2021 - April 8, 2022.